



08 May 2024

## ASX ANNOUNCEMENT (ASX:CBL)

### Contract award US General Services Administration

Control Bionics Ltd (ASX: CBL) is pleased to announce it has been awarded a US General Services Administration ('GSA') Multiple Award Schedule ('MAS') contract. This contract allows Control Bionics direct access to a vast market of government buyers, including federal, state and local agencies. CBL will benefit from the increased credibility and visibility through the awarding of this contract.

The GSA contract will both facilitate marketing and sales of our products with a more rapid sales process expected.

CBL has commenced work on our promotions campaign to access new sales through this contracted relationship.

This contract allows Control Bionics Inc (our US subsidiary) to sell US\$125,000 of Control Bionics technology over a 5-year period. The contract has 3 extensions for a possible total duration of 20 years. The total contract value is US\$500,000 with opportunities for repricing over the duration.

Once the initial \$125,000 has been invoiced, there opportunities to extend the total funding available.

Whilst CBL has for many years sold its solutions to customers who are funded by the US Government, this new contract allows us to market directly to a variety of Federal departments (such as the Veterans Administration). We expect our sales will be predominately focused on our flagship Trilogy solution.

This announcement was authorised by CBL CEO, Jeremy Steele.

#### About Control Bionics:

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in

terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. DROVE allows powered users the independence to operate their wheelchairs in their own homes for the first time.

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip®. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore and Japan.

## **Investors and Media**

Jeremy Steele – CEO and Managing Director  
[jsteele@controlbionics.com](mailto:jsteele@controlbionics.com)

Brett Crowley - Company Secretary  
[brettcrowley@controlbionics.com](mailto:brettcrowley@controlbionics.com)

For further information visit the website: <https://www.controlbionics.com/>